It revealed that sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year, from 9.6 billion kroner (£1.1 ...

It revealed that sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year, from 9.6 billion kroner (£1.1 ...

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth quarter of last year.

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

Many who would benefit from the drug find the idea of a weekly injection a turnoff. Novo Nordisk's recent announcement that Wegovy in a tablet proved as effective as the shots could open the ...

The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, are key to the company's beat. Combined, they brought in $24.9 billion for the year. That's compared ...

The company is spending billions to ramp up its Wegovy output as demand soars. "Emissions come with growth," said Katrine DiBona, corporate vice president of global public affairs and ...